- Home
- IFRX vs BTCM Comparison
IFRX vs BTCM Comparison
Compare IFRX & BTCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- BTCM
- Stock Information
- Founded
- IFRX 2007
- BTCM 2001
- Country
- IFRX Germany
- BTCM United States
- Employees
- IFRX N/A
- BTCM N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- BTCM EDP Services
- Sector
- IFRX Health Care
- BTCM Technology
- Exchange
- IFRX Nasdaq
- BTCM Nasdaq
- Market Cap
- IFRX 53.5M
- BTCM 47.8M
- IPO Year
- IFRX 2017
- BTCM 2013
- Fundamental
- Price
- IFRX $0.83
- BTCM $2.87
- Analyst Decision
- IFRX Strong Buy
- BTCM Hold
- Analyst Count
- IFRX 4
- BTCM 1
- Target Price
- IFRX $7.75
- BTCM N/A
- AVG Volume (30 Days)
- IFRX 198.5K
- BTCM 766.3K
- Earning Date
- IFRX 08-07-2025
- BTCM 08-22-2025
- Dividend Yield
- IFRX N/A
- BTCM N/A
- EPS Growth
- IFRX N/A
- BTCM N/A
- EPS
- IFRX N/A
- BTCM 0.62
- Revenue
- IFRX $191,224.00
- BTCM $32,921,999.00
- Revenue This Year
- IFRX N/A
- BTCM $14.32
- Revenue Next Year
- IFRX $1,276.37
- BTCM N/A
- P/E Ratio
- IFRX N/A
- BTCM $3.92
- Revenue Growth
- IFRX 54.36
- BTCM N/A
- 52 Week Low
- IFRX $0.71
- BTCM $1.22
- 52 Week High
- IFRX $2.82
- BTCM $8.07
- Technical
- Relative Strength Index (RSI)
- IFRX 44.92
- BTCM 50.26
- Support Level
- IFRX $0.74
- BTCM $2.59
- Resistance Level
- IFRX $0.86
- BTCM $2.93
- Average True Range (ATR)
- IFRX 0.07
- BTCM 0.26
- MACD
- IFRX -0.00
- BTCM -0.06
- Stochastic Oscillator
- IFRX 44.02
- BTCM 44.19
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About BTCM BIT Mining Limited ADS
BIT Mining Ltd is a cryptocurrency mining company, with a long-term plan to encompass the whole cryptocurrency value chain. Its business covers cryptocurrency mining, mining pool, data center operation and mining machine manufacturing. The company has a related and growing deployed Bitcoin mining machine capacity, owns three hydroelectric cryptocurrency mines with combined power capacity of 435MW and the entire mining pool business operated under BTC.com, including the domain name and wallet. It has also entered into a definitive agreement to acquire a 7 nanometer cryptocurrency mining machine manufacturer "Bee Computing", completing its vertical integration, making self-sufficient while also strengthening competitive position.